Metoclopramide 5/10 mg tabs — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Nausea & Vomiting

• Ondansetron
• Ondansetron 4/8 mg ODT/tabs

What Metoclopramide 5/10 mg tabs is approved for (FDA label)

Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

Source: Read the full FDA label on DailyMed. Label effective date: August 18, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Metoclopramide 5/10 mg tabs (FDA label)

WARNING: TARDIVE DYSKINESIA Metoclopramide, including metoclopramide tablets, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder. In patients treated with metoclopramide, including metoclopramide tablets, the risk of developing TD increases with duration of treatment and total cumulative dosage [ see Warnings and Precautions ( 5.1 )] . Metoclopramide is contraindicated in patients with a history of TD. Use metoclopramide tablets for the shortest duration of treatment and periodically reassess the need for continued treatment. Immediately discontinue metoclopramide in patients who develop signs or symptoms of TD [ see Warnings and Precautions ( 5.1 )] . In patients with symptomatic, documented gastroesophageal reflux, the maximum duration of metoclopramide tablets treatment is 12 weeks [ see Dosage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 )] . In patients with diabetic gastroparesis, avoid a total duration of treatment with metoclopramide products, including metoclopramide tablets, for longer than 12 weeks. If longer term use is unavoidable, routinely monitor for signs and symptoms of TD [ see Warnings and Precautions ( 5.1 )] . WARNING: TARDIVE DYSKINESIA See full prescribing information for complete boxed warning. Metoclopramide, including metoclopramide tablets, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder.

Source: FDA prescribing information (DailyMed). Set ID: 595439ae-cf01-821c-e063-6294a90af16a. SPL document ID: 59543a07-5813-821a-e063-6294a90ab735. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Metoclopramide 5/10 mg tabs (FDA label)

Tablets: 5 mg metoclopramide, USP: white, round, unscored, debossed “TV” on one side and “2204” on the other side. 10 mg metoclopramide, USP: white, round, scored, debossed “TEVA” on one side and “2203” above the score on the other side. Tablets: 5 mg and 10 mg metoclopramide ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 595439ae-cf01-821c-e063-6294a90af16a. SPL document ID: 59543a07-5813-821a-e063-6294a90ab735. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Metoclopramide 5/10 mg tabs (FDA label)

The following adverse reactions are described, or described in greater detail, in other sections of the labeling: Tardive dyskinesia [see Boxed Warning and Warnings and Precautions ( 5.1 )] Other extrapyramidal symptoms [see Warnings and Precautions ( 5.2 )] Neuroleptic malignant syndrome [see Warnings and Precautions ( 5.3 )] Depression [see Warnings and Precautions ( 5.4 )] Hypertension [see Warnings and Precautions ( 5.5 )] Fluid retention [see Warnings and Precautions ( 5.6 )] Hyperprolactinemia [see Warnings and Precautions ( 5.7 )] Effects on the ability to drive and operate machinery [see Warnings and Precautions ( 5.8 )] The following adverse reactions have been identified from clinical studies or postmarketing reports of metoclopramide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most common adverse reactions (in approximately 10% of patients receiving 10 mg of metoclopramide four times daily) were restlessness, drowsiness, fatigue, and lassitude.

Source: FDA prescribing information (DailyMed). Set ID: 595439ae-cf01-821c-e063-6294a90af16a. SPL document ID: 59543a07-5813-821a-e063-6294a90ab735. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Metoclopramide 5/10 mg tabs (FDA label)

Metoclopramide is contraindicated: In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide [see Warnings and Precautions ( 5.1 , 5.2 )] . When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage, mechanical obstruction, or perforation). In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor [see Warnings and Precautions ( 5.5 )] . In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures [see Adverse Reactions ( 6 )] . In patients with hypersensitivity to metoclopramide.

Source: FDA prescribing information (DailyMed). Set ID: 595439ae-cf01-821c-e063-6294a90af16a. SPL document ID: 59543a07-5813-821a-e063-6294a90ab735. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Metoclopramide 5/10 mg tabs (FDA label)

Tardive Dyskinesia (TD), Other Extrapyramidal Symptoms (EPS), and Neuroleptic Malignant Syndrome (NMS) : Avoid concomitant use of other drugs known to cause TD/EPS/NMS and avoid use in patients with Parkinson’s Disease. If symptoms occur, discontinue metoclopramide and seek immediate medical attention. ( 5.1 , 5.2 , 5.3 , 7.1 , 7.2 ) Depression and suicidal ideation/suicide : Avoid use. ( 5.4 ) 5.1 Tardive Dyskinesia Metoclopramide, including metoclopramide tablets, can cause tardive dyskinesia (TD), a syndrome of potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities. Metoclopramide, including metoclopramide tablets, may also suppress, or partially suppress, the signs of TD, and may delay the diagnosis of TD because it may mask the underlying disease process. The effect of this symptomatic suppression upon the long-term course of TD is unknown. TD may remit, partially or completely, if metoclopramide treatment is discontinued.

Source: FDA prescribing information (DailyMed). Set ID: 595439ae-cf01-821c-e063-6294a90af16a. SPL document ID: 59543a07-5813-821a-e063-6294a90ab735. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Metoclopramide 5/10 mg tabs (FDA label)

Antipsychotics : Potential for additive effects, including TD, EPS, and NMS; avoid concomitant use. ( 7.1 ) Central Nervous System (CNS) depressants : Increased risk of CNS depression. Avoid concomitant use and monitor for adverse reactions. ( 7.1 ) Strong CYP2D6 inhibitors (e.g., quinidine, bupropion, fluoxetine, and paroxetine) : See Full Prescribing Information for recommended dosage reductions. ( 2.1 , 2.3 , 7.1 ) Monoamine oxidase (MAO) inhibitors : Increased risk of hypertension; avoid concomitant use. ( 5.5 , 7.1 ) Additional drug interactions : See Full Prescribing Information. ( 7.1 , 7.2 ) 7.1 Effects of Other Drugs on Metoclopramide Table 3 displays the effects of other drugs on metoclopramide. Table 3. Effects of Other Drugs on Metoclopramide Antipsychotics Clinical Impact Potential for additive effects, including increased frequency and severity of tardive dyskinesia (TD), other extrapyramidal symptoms (EPS), and neuroleptic malignant syndrome (NMS).

Source: FDA prescribing information (DailyMed). Set ID: 595439ae-cf01-821c-e063-6294a90af16a. SPL document ID: 59543a07-5813-821a-e063-6294a90ab735. Label effective date: August 18, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.